|  |
| --- |
| **Thursday, October 27, 2022** |
| **Title** | **Upon completion of this course, learners will****be better able to:** | **Faculty Information** | **CPE Information** |
| **A Modern Approach to Clinician Safety and Well-being** 8:15am – 9:15am | 1. Discuss the impact of the pandemic on society’s mental health and destructive behaviors
2. Recognize the impact of the pandemic and society’s response on clinicians’ safety and well-being
3. Apply new knowledge to assist in the

building of improved systems for clinician safety and well-being | Gerard Clancy, MDSenior Associate Dean for External Affairs Professor of Psychiatry and Emergency MedicineUI Carver College of Medicine | UAN:0107-9999-22-322-L04-P0.1 CEU/1.0 Hours Knowledge-based |
| **Reproductive Health in Rheumatic Diseases**9:15am – 10:00am | 1. Discuss the unique safety issues of different forms of contraception in patients with rheumatic disease
2. Explain the importance of pre-pregnancy risk assessment in patients with rheumatic disease
3. Describe unique disease-specific features in pregnant women with rheumatic disease
4. Discuss the safety of rheumatology

medications in pregnancy and lactation | Brittany Bettendorf, MD Clinical Assistant Professor Division of ImmunologyUI Carver College of Medicine | UAN:0107-9999-22-323-L01-P0.075 CEU/0.75 Hours Knowledge-based |
| **Shared Care of Oncology Patients: Managing the Mayhem of Oral Oncolytic Agents** 10:15am – 11:00am | 1. Describe the mechanism of action of the groups of oral oncolytic agents discussed
2. Identify common side effects associated with the agents discussed
3. Design supportive care plans to effectively manage adverse effects of the agents discussed
 | Susan Fajardo, PharmD, BCACP Clinical Pharmacy Specialist Hematology/OncologyUniversity of Iowa Hospitals and Clinics | UAN:0107-9999-22-324-L01-P0.075 CEU/0.75 Hours Knowledge-based |

|  |
| --- |
| **Thursday, October 27, 2022** |
| **Title** | **Upon completion of this course, learners will****be better able to:** | **Faculty Information** | **CPE Information** |
| **GLP-1 Receptor Agonists and Obesity: What Are You Weighting For?** 11:00am – 11:45am | 1. Discuss pharmacology of GLP-1 receptor agonists
2. Describe the role of GLP-1 receptor agonists in treatment of obesity
3. Identify candidates for GLP-1 receptor agonists in patients with obesity
4. Create a care plan for a patient with obesity that includes a GLP-1 receptor agonist as

appropriate therapy | Leon Jons, MDClinical Associate ProfessorDivision of Endocrinology and Metabolism UI Carver College of MedicineTracy Weber, PharmD, BCACP Clinical Pharmacy Specialist University of Iowa | UAN:0107-9999-22-325-L01-P0.075 CEU/0.75 Hours Knowledge-based |
| **Evidence-based Medicine Updates of Pharmacotherapy Interventions in the Emergency Department / Hot Topics in Health System Medicine** 1:00pm – 2:30pm | 1. Discuss the current evidence for emerging pharmacotherapy interventions in the emergency department
2. Discuss pharmacotherapy updates in hospital medicine
3. Identify trending topics in critical care medicine
 | Brett Faine, PharmD, MS Clinical Associate ProfessorDepartment of Emergency Medicine and Pharmacy, UIHCMike Gassmann PharmD, BCPS Inpatient Clinical Pharmacist Department of Pharmacy, UIHCKaty Rolfes, PharmD, BCPS, BCCCP Critical Care Clinical Pharmacist Department of Pharmacy, UIHC | UAN:0107-9999-22-326-L01-P0.15 CEU/1.5 Hours Knowledge-based |

|  |
| --- |
| **Friday October 28, 2022** |
| **Title** | **Upon completion of this course, learners will****be better able to:** | **Faculty Information** | **CPE Information** |
| **Quality Improvement in Healthcare: The Pipeline is the Process**8:15am – 9:15am | 1. Describe the role of professional development in driving improvement
2. Discuss the PERMA (Positive Emotions, Engagement, Relationships, Meaning, Accomplishment) model and how to apply it to developing healthcare professionals
 | Kierstin Cates Kennedy, MD, MSHA, FACP, SFHMChief Medical OfficerUniversity of Alabama at Birmingham (UAB) Medicine | UAN:0107-9999-22-327-L04-P0.1 CEU/1.0 Hours Knowledge-based |
| **Changing Landscape of Metastatic Non- Small Cell Lung Cancer (NSCLC)** 9:15am – 10:000am | 1. Discuss the efficacy and impact of immunotherapy in the management of Metastatic Non-Small Cell Lung Cancer (NSCLC)
2. Discuss the actionable and driver molecular alterations in NSCLC
3. Compare efficacy of targeted therapy to conventional therapy in NSCLC
 | Mohammed Furqan, MD Clinical Associate ProfessorDivision of Hematology and Oncology UI Carver College of Medicine | UAN:0107-9999-22-328-L01-P0.075 CEU/0.75 Hours Knowledge-based |
| **Managing Inpatients with Hypertriglyceridemia and Insulin Protocols** 10:15am – 10:45am | 1. Discuss the etiology and pathophysiology of hypertriglyceridemia
2. Describe the complications of hypertriglyceridemia in hospitalized patients
3. Discuss the management of hypertriglyceridemia in hospitalized patients
 | Marcelo Correia MD, MSc, PhD, DABOM Clinical Assistant ProfessorDepartment of Internal Medicine Division of Endocrinology, UI Carver College of MedicineSarah Nolan, PA-C Diabetes Management PADepartment of Internal Medicine Division of Endocrinology, UI Carver College of Medicine | UAN:0107-9999-22-329-L01-P0.05 CEU/0.5 Hours Knowledge-based |
| **Monoclonal Antibodies for the Prevention and Treatment of COVID-19** 10:45am – 11:45am | 1. Describe currently available antibody products and their place in therapy in the treatment and prevention of COVID-19
2. Explain the risks and benefits of monoclonal antibody therapy to their patients
3. Discuss the use of monoclonal antibody therapy in the treatment of COVID-19
 | Emily Walsh, PharmD, BCACPDivision of Immunology/Rheumatology UI Health Care | UAN:0107-9999-22-330-L01-P0.1 CEU/1.0 Hours Knowledge-based |

|  |
| --- |
| **Friday October 28, 2022** |
| **Title** | **Upon completion of this course, learners will****be better able to:** | **Faculty Information** | **CPE Information** |
| **Continuous Glucose Monitors (CGM) in Primary Care** 1:00pm – 2:30pm | 1. Discuss the use of Continuous Glucose Monitor (CGM) technology
2. Identify criteria for use of CGM
3. Review interpretation of CGM data
4. Explain specific precautions, pitfalls, and patient factors to consider with CGM use
 | Amie Ogunsakin, MD Clinical Assistant ProfessorDepartment of Internal Medicine Division of Endocrinology, UI Carver College of MedicineBianca Carlson, PA-C Diabetes Management PADepartment of Internal Medicine Division of Endocrinology, UI Carver College of Medicine | UAN:0107-9999-22-331-L01-P0.15 CEU/1.5 Hours Knowledge-based |
| **Updates in Chronic Pain Management** 1:00pm – 2:30pm | 1. Describe the changes in the updated CDC Opioid Prescribing Guidelines and how these will affect clinical practice
2. Discuss the current data supporting cognitive behavioral therapies for chronic pain
3. Describe the status of what is known about pain and related effects seen after COVID infection
 | Lee Kral, PharmD, FASHP, CHWC Clinical Assistant Professor, Dept of AnesthesiaUI Carver College of MedicineBeth Dinoff, PhDClinical Associate Professor, Dept of AnesthesiaUI Carver College of MedicineEmma Murter, PharmDPGY2 Pain and Palliative Care Pharmacy ResidentUI College of Pharmacy | UAN:0107-9999-22-332-L08-P0.15 CEU/1.5 Hours Knowledge-based |
| **Chimeric Antigen Receptor T-Cells, New Tools for Immune System Engineering in Oncology**2:45pm – 4:15pm | 1. Identify chimeric antigen receptor T cell therapies and the current indications for their use
2. Describe the process of CAR T cell collection, infusion, and monitoring
 | Christopher Strouse MD Clinical Assistant ProfessorDepartment of Internal Medicine UI Carver College of Medicine | UAN:0107-9999-22-333-L01-P0.15 CEU/1.5 Hours Knowledge-based |

|  |  |  |  |
| --- | --- | --- | --- |
| Chimeric Antigen Receptor T-Cells, New Tools for Immune System Engineering in Oncology(continued) | 1. Recognize short and long-term side effects of treatment with chimeric antigen receptor T cells
2. Describe the financial implications of chimeric antigen receptor T cell treatments from the perspective of patients, the institution, and

the health care system | Jonathan Lochner, PharmD Clinical PharmacistDepartments of Internal Medicine and PharmacyUniversity of Iowa Health Care |  |
|  | 1. Discuss CDC vaccine updates for Hepatitis B, | Allison Bernard, PharmD, BCACP Clinical Pharmacy Specialist – Family MedicineDepartment of Pharmacy University of Iowa Health CareSarah Greiner, PharmDPGY2 Ambulatory Care Pharmacy Resident Department of PharmacyUniversity of Iowa Health CareWilliam L. Iverson, MD Clinical ProfessorDivision of General Internal MedicineUI Carver College of Medicine and Iowa City Veterans Affairs Medical Center |  |
|  | HPV, Influenza, Pneumococcal, Rabies, Shingrix, |  |
|  | and Tdap |  |
| **Vaccine Updates**2:45pm – 4:15pm | 1. Apply Advisory Committee on Immunization Practices (ACIP) Guidelines to patient cases to provide appropriate vaccine recommendations
2. Compare 23-valent pneumococcal

polysaccharide vaccine (PPSV23) and 20-valent | UAN:0107-9999-22-334-L06-P0.15 CEU/1.5 Hours Application-based |
|  | pneumococcal conjugate vaccine (PCV20) |  |
|  | 4. Recognize differences between the 2-dose |  |
|  | series and 3-dose series for Human |  |
|  | Papillomavirus (HPV) Vaccine |  |

**Additional CPE Information**

**Faculty Disclosure:**

Brett Faine reports sponsored research projects by Spero Therapeutics, Inc.

Mohammed Furqan is a member of the following advisory committees and reports sponsored research by the pharmaceutical companies listed below: Advisory; -Jazz Pharmaceuticals -Advisory; -Mirat Therapeutics -Advisory; -Abbvie -Advisory; -AstraZeneca Pharmaceuticals LP -Advisory; -Beigene - Advisory; -Janssen Pharmaceutica -Advisory; -Abbvie -Advisory; -AstraZeneca Pharmaceuticals LP -Advisory; -Beigene -Advisory; -Janssen Pharmaceutica -Advisory; -Mirat Therapeutics -Advisory; Helping in reviewing data; -Novartis -AbbVie, Inc.; Altor BioScience, LLC; Amgen, Inc.; Aprea Therapeutics; AstraZeneca LP; AstraZeneca Pharmaceuticals LP; BeiGene, Ltd.; Bristol-Myers Squibb Company; Celgene Corporation; Checkmate Pharmaceuticals; Elicio Therapeutics, Inc.; Genentech, Inc.; Genmab US Inc.; Gilead Sciences, Inc.; Incyte Corporation; Inhibrx, Inc.; Merck Sharp &amp; Dohme LLC; Mirati Therapeutics, Inc; Novartis Pharmaceuticals Corporation; Pharmaceutical Research Associates; PPD Investigator Services, LLC; SOPHiA GENETICS; -Sponsored Research - 07/14/2022PDF

Marcelo Correia reports sponsored research by the pharmaceutical companies listed below:

research; -Eli Lilly and Company -Research; -Novartis -Consultant; Research; -Novo Nordisk Pharmaceuticals, Inc. -research; -Eli Lilly and Company - Research; -Novartis -Consultant; Research; -Novo Nordisk Pharmaceuticals, Inc. -Eli Lilly &amp; Company; Novartis Pharmaceuticals Corporation; Novo Nordisk, Inc.; -Sponsored Research - 03/29/2022PDF

All relevant financial relationships have been mitigated.

All other faculty members for Progress 2022 have no relevant financial relationships with ineligible companies to disclose.

**Off-Label Use of Medications:** Off-label use of medications will be discussed during the scheduled presentations:

* Evidence-based Medicine Updates of Pharmacotherapy Interventions in the Emergency Department / Hot Topics in Health System Medicine
* Changing Landscape of Metastatic Non-Small Cell Lung Cancer (NSCLC)

CEimpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

*To obtain the number of contact hours of continuing pharmacy education noted for each course listed, participants must participate in the course, successfully pass the exam (if applicable), and complete an evaluation. The CPE Statement of Credit can then be accessed on CPE Monitor,* [*www.MyCPEMonitor.net.*](http://www.mycpemonitor.net/)

***You must complete these requirements within 30 days of the date of the live CPE event. Late submissions will not transmit to CPE Monitor and CPE credit will not be provided.***

**Target Audience:** Pharmacists **Course Format:** Live, in-person **Financial Support:** None

**Course Fee:** Pharmacist/Allied Health Professional $225- 2 days / $125 – 1 day Resident $135 – 2 days / $70 – 1 day

Student $100 – 2 days / $55 – 1 day